Health News Archive - May 02, 2011
MOUNTAIN VIEW, Calif., May 2, 2011 /PRNewswire/ -- Omnicell, Inc.
SAN DIEGO, May 2, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, said today that it will be participating in the Tenth Annual JMP Securities Research Conference on Tuesday, May 10. The presentation by John Dahldorf, chief financial officer, will begin at 10:30 a.m., Pacific Daylight Time (1:30 p.m., Eastern Daylight Time). The presentation will be available through the conference website at http://www.wsw.com/webcast/jmp13/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive.
BOTHELL, WA and VANCOUVER, May 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's first quarter 2011 financial results will be released on Monday, May 9, 2011 after the NASDAQ Global Market closes at 4:00 p.m.
SAN DIEGO, May 2, 2011 /PRNewswire/ -- OrexigenÂ® Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of obesity, will announce first quarter ended March 31, 2011 financial results on Monday, May 9, 2011 before the markets open.
MILFORD, Mass., May 2, 2011 /PRNewswire/ -- SeraCare Life Sciences announced today that the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded a new contract to SeraCare, replacing the current contract which expired on April 30, 2011.
Experimental research in bisphenol A, (BPA) suggests that prenatal BPA exposure causes asthma in mice.
EAST BRUNSWICK, N.J., May 2, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc.
BLUE BELL, Pa., May 2, 2011 /PRNewswire/ -- Evolution Marketing Research, the next-generation pharmaceutical marketing research and consulting company, announced its 2010 sales revenue of $12,500,000, representing 11% growth since 2009.
ALISO VIEJO, Calif., May 2, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter ended March 31, 2011 after market close on Monday, May 9, 2011.
NATICK, Mass., May 2, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions of the Heart Rhythm Society (HRS), May 4 - 7 in San Francisco.